Develop innovative treatments for hematological disorders. Focus on musculoskeletal disorder therapies. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 87% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 36% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 87% a year on average.
There is $287.4M in the vault; even if every debt were paid off, $270.5M would remain.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 28/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 43/100. For a turnaround signal, the stock first needs to close the gap with the market.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, KROS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KROS does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (58/100) says the stock isn’t cheap.